Insights in ROP

References

• Kinsey VE: Retrolental fibroplasia: Etiology of retrolental fibroplasia and preliminary report of the cooperative study of retrolental fibroplasia. Trans Am Acad Ophthalmol Otolaryngol 1955; 59: 15–24.
   PubMedGoogle Scholar
• Kinsey VE: Retrolental fibroplasia: Cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 1956; 56: 481–543.
   PubMed Web of Science ®Google Scholar
• Biglan AW, Brown DR, Reynolds JD, et al.: Risk factors associated with retrolental fibroplasia. Ophthalmology 1984; 91: 1504–1511.
   PubMed Web of Science ®Google Scholar
• Terry TL: Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens—I. Preliminary report. Am J Ophthalmol 1942; 25: 203–204.
   Google Scholar
• Terry TL: Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants. II. Report of cases—clinical aspects. Arch Ophthalmol 1943; 29: 36–53.
   Google Scholar
• Jacobson RM, Feinstein AR: Oxygen as a cause of blindness in premature infants: “Autopsy” of a decade of errors in clinical epidemiological research. J Clin Epidemiol 1992; 45: 1265–1287.
   Web of Science ®Google Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy or prematurity: Preliminary results. Arch Ophthalmol 1988; 106: 471–479.
   PubMedGoogle Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity: 3 month outcome. Arch Ophthalmol 1990; 108: 195–204.
   PubMedGoogle Scholar
• Reynolds JD, Hardy RJ, Kennedy KA, et al., for the Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group: Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med 1998; 338: 1572–1576.
   Web of Science ®Google Scholar
• The STOP-ROP Multicenter Study Group: Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial—I: Primary outcomes. Pediatrics 2000; 105: 295–310.
   Web of Science ®Google Scholar
• Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity. Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684–1696.
   PubMed Web of Science ®Google Scholar
• Kupfer C, McManus E, Berlage N. History of the National Eye Institute, 1968-2000. Bethesda: National Eye Institute; 2009.
   Google Scholar
• Palmer EA, Flynn JT, Hardy RJ, et al., for the Cryotherapy for Retinopathy of Prematurity Cooperative Group: Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98: 1628–1640.
   PubMed Web of Science ®Google Scholar
• Flynn JT, Chan-Ling T: Retinopathy of prematurity: Two distinct mechanisms that underlie Zone I and Zone II disease. Am J Ophthalmol 2006; 142: 46–59.
   PubMed Web of Science ®Google Scholar
• Silverman WA: A cautionary tale about supplemental oxygen: The albatross of neonatal medicine. Pediatrics 2004; 113: 394–396.
   PubMed Web of Science ®Google Scholar
• Committee for the Classification of Retinopathy of Prematurity: An international classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102: 1130–1134.
   PubMed Web of Science ®Google Scholar
• International Committee for the Classification of the Late Stages of Retinopathy of Prematurity: An international classification of retinopathy of prematurity—II. The classification of retinal detachment. Arch Ophthalmol 1987; 105: 906–912.
   Google Scholar
• An International Committee for the Classification of Retinopathy of Prematurity: The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123: 991–999.
   PubMedGoogle Scholar
• Repka MX, Palmer EA, Tung B, for the Cryotherapy for Retinopathy of Prematurity Cooperative Group: Involution of retinopathy of prematurity. Arch Ophthalmol 2000; 118: 645–649.
   Google Scholar
• Reynolds JD, Hardy RJ, Palmer EA: Incidence and severity of retinopathy of prematurity. J AAPOS 1999; 3: 321–322.
   Web of Science ®Google Scholar
• Early Treatment of Retinopathy of Prematurity Cooperative Group: The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005; 116: 15–23.
   Web of Science ®Google Scholar
• Reynolds JD, Dobson V, Quinn GE, et al., for the CRYO-ROP and LIGHT-ROP Cooperative Groups: Evidence-based screening criteria for retinopathy of prematurity. Arch Ophthalmol 2002; 120: 1470–1476.
   Google Scholar
• Section on Ophthalmology, American Academy of Pediatrics, American Academy of Ophthalmology, and American Association of Pediatric Ophthalmology and Strabismus: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572–576.
   PubMed Web of Science ®Google Scholar
• Section on Ophthalmology, American Academy of Pediatrics, American Academy of Ophthalmology, and American Association of Pediatric Ophthalmology and Strabismus: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 118: 1324.
   Web of Science ®Google Scholar
• American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus and American Association of Certified Orthoptists: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131: 189–195.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ, for the BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl Med 2011; 364: 603–615.
   Web of Science ®Google Scholar
• Reynolds JD: Bevacizumab for retinopathy of prematurity. N Engl J Med 2011; 364: 677–678.
   PubMed Web of Science ®Google Scholar
• Hu J, Blair MP, Shapiro MJ, et al.: Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130: 1000–1006.
   PubMed Web of Science ®Google Scholar
• Mireskandari K, Adams GW, Tehrani NN: Recurrence of retinopathy of prematurity following bevacizumab monotherapy: Is it only the tip of the iceberg? JAMA Ophthalmol 2013; 131: 544–545.
   Web of Science ®Google Scholar
• Hoang QV, Kiernan DF, Chau FY, et al.: Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol 2010; 128: 1080–1081.
   Google Scholar
• Lee JM, Kodsi SR, Gaffar MA, et al.: Cardiopulmonary arrest following administration of Cyclomydril eyedrops for outpatient retinopathy of prematurity screening. J AAPOS 2014; 18: 183–184.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al.: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855–858.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al.: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179–2182.
   PubMed Web of Science ®Google Scholar